Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation

• Príomhchruthaitheoirí: Dusan Ruzic (Údar), Bernhard Ellinger (Údar), Nemanja Djokovic (Údar), Juan F. Santibanez (Údar), Sheraz Gul (Údar), Milan Beljkas (Údar), Ana Djuric (Údar), Arasu Ganesan (Údar), Aleksandar Pavic (Údar), Tatjana Srdic-Rajic (Údar), Milos Petkovic (Údar), Katarina Nikolic (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: MDPI AG, 2022-11-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Isoform-selective histone deacetylase (HDAC) inhibition is promoted as a rational strategy to develop safer anti-cancer drugs compared to non-selective HDAC inhibitors. Despite this presumed benefit, considerably more non-selective HDAC inhibitors have undergone clinical trials. In this report, we d...